Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors
US-2015366955-A9 · Dec 24, 2015 · US
Recombinant cells and organisms having persistent nonstandard amino acid dependence and methods of making them
US9834775B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9834775-B2 |
| Application number | US-201415025406-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 26, 2014 |
| Priority date | Sep 27, 2013 |
| Publication date | Dec 5, 2017 |
| Grant date | Dec 5, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Recombinant cells and recombinant organisms persistently expressing nonstandard amino acids (NSAAs) are provided. Methods of making recombinant cells and recombinant organisms dependent on persistently expressing NSAAs for survival are also provided. These methods may be used to make safe recombinant cells and recombinant organisms and/or to provide a selective pressure to maintain one or more reassigned codon functions in recombinant cells and recombinant organisms.
First claim
Opening claim text (preview).
What is claimed is: 1. A genetically modified Escherichia coli ( E. coli ) cell comprising: an essential polypeptide encoded by an essential nucleic acid sequence, wherein the essential polypeptide comprises a recoded adenylate kinase (adk) comprising I4A, L6V, V103A, L178bipA, Y182V, and T191I substitutions; a recoded alanyl-tRNA synthetase (alaS) comprising M1bipA, F90A, F293A, L338bipA, M342A, and L349P substitutions; a recoded methionyl-tRNA synthetase (metG) comprising M485A, F502G, and L503bipA substitutions; a recoded phosphoglycerate kinase (pgk) comprising V185A, I187A, I211G, and L297bipA substitutions; or a recoded tyrosol-tRNA synthetase (tyrS) comprising F706A, W778F, T787V, F823G, L907bipA, and V919A substitutions, wherein bipA is L-4,4′-bisphenylalanine. 2. The cell of claim 1 , comprising two or more essential polypeptides encoded by two or more essential nucleic acid sequences. 3. The cell of claim 1 wherein the essential polypeptide comprises the recoded adk comprising I4A, L6V, V103A, L178bipA, Y182V, and T191I substitutions. 4. The cell of claim 1 wherein the essential polypeptide comprises the recoded alaS comprising M1bipA, F90A, F293A, L338bipA, M342A, and L349P substitutions. 5. The cell of claim 1 wherein the essential polypeptide comprises the recoded metG comprising M485A, F502G, and L503bipA substitutions. 6. The cell of claim 1 wherein the essential polypeptide comprises the recoded pgk comprising V185A, I187A, I211G, and L297bipA substitutions. 7. The cell of claim 1 wherein the essential polypeptide comprises the recoded tyrS comprising F706A, W778F, T787V, F823G, L907bipA, and V919A substitutions.
Assignees
Inventors
Classifications
- C12N1/36Primary
Adaptation or attenuation of cells · CPC title
Vectors comprising a coding region that has been codon optimised for expression in a respective host · CPC title
- C12N15/65Primary
using markers (enzymes used as markers C12N15/52) · CPC title
Genes encoding for enzymes or proenzymes · CPC title
inhibiting translation · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9834775B2 cover?
- Recombinant cells and recombinant organisms persistently expressing nonstandard amino acids (NSAAs) are provided. Methods of making recombinant cells and recombinant organisms dependent on persistently expressing NSAAs for survival are also provided. These methods may be used to make safe recombinant cells and recombinant organisms and/or to provide a selective pressure to maintain one or more …
- Who is the assignee on this patent?
- Harvard College
- What technology area does this patent fall under?
- Primary CPC classification C12N1/36. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Dec 05 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).